BHC
Price
$6.05
Change
+$0.04 (+0.67%)
Updated
Oct 17 closing price
Capitalization
2.23B
11 days until earnings call
VTRS
Price
$10.17
Change
+$0.07 (+0.69%)
Updated
Oct 17 closing price
Capitalization
11.86B
19 days until earnings call
Interact to see
Advertisement

BHC vs VTRS

Header iconBHC vs VTRS Comparison
Open Charts BHC vs VTRSBanner chart's image
Bausch Health Companies
Price$6.05
Change+$0.04 (+0.67%)
Volume$1.12M
Capitalization2.23B
Viatris
Price$10.17
Change+$0.07 (+0.69%)
Volume$5.51M
Capitalization11.86B
BHC vs VTRS Comparison Chart in %
BHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHC vs. VTRS commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHC is a Hold and VTRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (BHC: $6.05 vs. VTRS: $10.17)
Brand notoriety: BHC: Notable vs. VTRS: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BHC: 41% vs. VTRS: 60%
Market capitalization -- BHC: $2.23B vs. VTRS: $11.86B
BHC [@Pharmaceuticals: Generic] is valued at $2.23B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $11.86B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.85B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.96B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHC’s FA Score shows that 0 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • BHC’s FA Score: 0 green, 5 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, VTRS is a better buy in the long-term than BHC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHC’s TA Score shows that 3 TA indicator(s) are bullish while VTRS’s TA Score has 6 bullish TA indicator(s).

  • BHC’s TA Score: 3 bullish, 5 bearish.
  • VTRS’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than BHC.

Price Growth

BHC (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +4.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.79%. For the same industry, the average monthly price growth was +4.23%, and the average quarterly price growth was +51.45%.

Reported Earning Dates

BHC is expected to report earnings on Oct 29, 2025.

VTRS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.79% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($11.9B) has a higher market cap than BHC($2.24B). VTRS has higher P/E ratio than BHC: VTRS (236.20) vs BHC (23.27). VTRS YTD gains are higher at: -15.148 vs. BHC (-24.938). BHC has higher annual earnings (EBITDA): 3B vs. VTRS (-493.3M). BHC has more cash in the bank: 1.73B vs. VTRS (809M). VTRS has less debt than BHC: VTRS (14.8B) vs BHC (21.7B). VTRS has higher revenues than BHC: VTRS (14.1B) vs BHC (9.86B).
BHCVTRSBHC / VTRS
Capitalization2.24B11.9B19%
EBITDA3B-493.3M-608%
Gain YTD-24.938-15.148165%
P/E Ratio23.27236.2010%
Revenue9.86B14.1B70%
Total Cash1.73B809M213%
Total Debt21.7B14.8B147%
FUNDAMENTALS RATINGS
BHC vs VTRS: Fundamental Ratings
BHC
VTRS
OUTLOOK RATING
1..100
6127
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
6246
P/E GROWTH RATING
1..100
441
SEASONALITY SCORE
1..100
3985

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is in the same range as BHC (35) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

VTRS's Profit vs Risk Rating (100) in the null industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

VTRS's SMR Rating (96) in the null industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

VTRS's Price Growth Rating (46) in the null industry is in the same range as BHC (62) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is somewhat better than the same rating for BHC (44) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew somewhat faster than BHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHCVTRS
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 1 day ago
63%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
63%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
64%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
60%
Advances
ODDS (%)
N/A
Bullish Trend 1 day ago
68%
Declines
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 26 days ago
65%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
68%
Aroon
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
BHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HYFI37.740.15
+0.40%
AB High Yield ETF
EBI54.200.21
+0.39%
The RBB Fund Trust Longview Advantage ETF
BRLN51.500.07
+0.14%
iShares Floating Rate Loan Active ETF
MMIT24.380.01
+0.04%
NYLI MacKay Muni Intermediate ETF
JJETF5.50N/A
N/A
Barclays Bank PLC

BHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHC has been loosely correlated with AMRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if BHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHC
1D Price
Change %
BHC100%
+0.67%
AMRX - BHC
38%
Loosely correlated
+0.51%
AMPH - BHC
32%
Poorly correlated
+2.41%
VTRS - BHC
30%
Poorly correlated
+0.69%
TEVA - BHC
27%
Poorly correlated
-1.63%
DRRX - BHC
26%
Poorly correlated
N/A
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
+0.69%
ELAN - VTRS
54%
Loosely correlated
+4.39%
ZTS - VTRS
47%
Loosely correlated
+0.56%
AMRX - VTRS
45%
Loosely correlated
+0.51%
EBS - VTRS
40%
Loosely correlated
-2.55%
COLL - VTRS
39%
Loosely correlated
+2.20%
More